EPID-02. SURVIVAL BENEFIT OF GLIOBLASTOMA PATIENTS AFTER FDA APPROVAL OF BEVACIZUMAB, A POPULATION-BASED STUDY USING SEER, TCR, AND NCDB DATABASES
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.